

Bluyssen H

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4582693/publications.pdf>

Version: 2024-02-01

55
papers

2,491
citations

172207

29
h-index

205818

48
g-index

56
all docs

56
docs citations

56
times ranked

3856
citing authors

#	ARTICLE	IF	CITATIONS
1	A Positive Feedback Amplifier Circuit That Regulates Interferon (IFN)-Stimulated Gene Expression and Controls Type I and Type II IFN Responses. <i>Frontiers in Immunology</i> , 2018, 9, 1135.	2.2	222
2	Combinatorial association and abundance of components of interferon-stimulated gene factor 3 dictate the selectivity of interferon responses.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995, 92, 5645-5649.	3.3	143
3	Stat2 Is a Transcriptional Activator That Requires Sequence-specific Contacts Provided by Stat1 and p48 for Stable Interaction with DNA. <i>Journal of Biological Chemistry</i> , 1997, 272, 4600-4605.	1.6	135
4	ISGF3 \hat{I} p48, a specificity switch for interferon activated transcription factors. <i>Cytokine and Growth Factor Reviews</i> , 1996, 7, 11-17.	3.2	129
5	The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. <i>Cytokine and Growth Factor Reviews</i> , 2016, 29, 71-81.	3.2	106
6	Expression of pre-selected TMEMs with predicted ER localization as potential classifiers of ccRCC tumors. <i>BMC Cancer</i> , 2015, 15, 518.	1.1	105
7	Genomics and epigenomics of clear cell renal cell carcinoma: Recent developments and potential applications. <i>Cancer Letters</i> , 2013, 341, 111-126.	3.2	101
8	Regulation of Interferon- \hat{I} Responsiveness by the Duration of Janus Kinase Activity. <i>Journal of Biological Chemistry</i> , 1997, 272, 21872-21877.	1.6	86
9	STAT2/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1. <i>Biochemical Journal</i> , 2015, 466, 511-524.	1.7	83
10	STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFN \hat{I} ³ , TLR4 and IL-6 in vascular disease. <i>Cytokine and Growth Factor Reviews</i> , 2011, 22, 211-219.	3.2	80
11	Broadly Altered Gene Expression in Blood Leukocytes in Essential Hypertension Is Absent During Treatment. <i>Hypertension</i> , 2004, 43, 947-951.	1.3	73
12	Rapid determination of adenoviral vector titers by quantitative real-time PCR. <i>Journal of Virological Methods</i> , 2001, 93, 181-188.	1.0	65
13	STAT1-Dependent Signal Integration between IFN \hat{I} ³ and TLR4 in Vascular Cells Reflect Pro-Atherogenic Responses in Human Atherosclerosis. <i>PLoS ONE</i> , 2014, 9, e113318.	1.1	63
14	Damage-associated molecular pattern activated Toll-like receptor 4 signalling modulates blood pressure in l-NAME-induced hypertension. <i>Cardiovascular Research</i> , 2014, 101, 464-472.	1.8	61
15	Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease. <i>Oncotarget</i> , 2016, 7, 48788-48812.	0.8	60
16	Regulation of gene expression by dietary Ca ²⁺ in kidneys of 25-hydroxyvitamin D ₃ -1 \hat{I} \hat{I} -hydroxylase knockout mice. <i>Kidney International</i> , 2004, 65, 531-539.	2.6	59
17	Structure, Chromosome Localization, and Regulation of Expression of the Interferon-Regulated Mouse Irf54/Irf56 Gene Family. <i>Genomics</i> , 1994, 24, 137-148.	1.3	56
18	IFN \hat{I} ³ -dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells. <i>American Journal of Physiology - Cell Physiology</i> , 2010, 299, C354-C362.	2.1	56

#	ARTICLE	IF	CITATIONS
19	Inflammatory Response Leads to Neuronal Death in Human Post-Mortem Cerebral Cortex in Patients with COVID-19. ACS Chemical Neuroscience, 2021, 12, 2143-2150.	1.7	50
20	Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates. Molecular Cancer, 2018, 17, 116.	7.9	48
21	Fibronectin is a hypoxia-independent target of the tumor suppressor VHL. FEBS Letters, 2004, 556, 137-142.	1.3	47
22	A type I IFN-Flt3 ligand axis augments plasmacytoid dendritic cell development from common lymphoid progenitors. Journal of Experimental Medicine, 2013, 210, 2515-2522.	4.2	47
23	STAT1-mediated signal integration between IFN β and LPS leads to increased EC and SMC activation and monocyte adhesion. American Journal of Physiology - Cell Physiology, 2011, 300, C1337-C1344.	2.1	46
24	Resistance to oxidative stress by chronic infusion of angiotensin II in mouse kidney is not mediated by the AT2 receptor. American Journal of Physiology - Renal Physiology, 2005, 288, F1191-F1200.	1.3	40
25	The interferon-stimulated gene 54 K promoter contains two adjacent functional interferon-stimulated response elements of different strength, which act synergistically for maximal interferon-alpha inducibility. FEBS Journal, 1994, 220, 395-402.	0.2	35
26	Potential Approaches and Recent Advances in Biomarker Discovery in Clear-Cell Renal Cell Carcinoma. Journal of Cancer, 2015, 6, 1105-1113.	1.2	35
27	A theoretical antioxidant pharmacophore for natural hydroxycinnamic acids. Open Chemistry, 2015, 13, .	1.0	35
28	FUT11 as a potential biomarker of clear cell renal cell carcinoma progression based on meta-analysis of gene expression data. Tumor Biology, 2014, 35, 2607-2617.	0.8	34
29	Signal Integration of IFN-I and IFN-II With TLR4 Involves Sequential Recruitment of STAT1-Complexes and NF κ B to Enhance Pro-inflammatory Transcription. Frontiers in Immunology, 2019, 10, 1253.	2.2	34
30	STAT1 and IRF8 in Vascular Inflammation and Cardiovascular Disease: Diagnostic and Therapeutic Potential. International Reviews of Immunology, 2016, 35, 434-454.	1.5	33
31	Identification of STAT1 and STAT3 Specific Inhibitors Using Comparative Virtual Screening and Docking Validation. PLoS ONE, 2015, 10, e0116688.	1.1	32
32	Nitric Oxide-Dependent and Nitric Oxide-Independent Transcriptional Responses to High Shear Stress in Endothelial Cells. Hypertension, 2005, 45, 672-680.	1.3	29
33	Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy. Frontiers in Immunology, 2022, 13, .	2.2	29
34	In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity. European Journal of Pharmacology, 2013, 720, 38-48.	1.7	26
35	Data Mining of Atherosclerotic Plaque Transcriptomes Predicts STAT1-Dependent Inflammatory Signal Integration in Vascular Disease. International Journal of Molecular Sciences, 2014, 15, 14313-14331.	1.8	24
36	Transcriptome-based identification of pro- and antioxidative gene expression in kidney cortex of nitric oxide-depleted rats. Physiological Genomics, 2007, 28, 158-167.	1.0	21

#	ARTICLE	IF	CITATIONS
37	Increased expression of SOCS3 in monocytes and SOCS1 in lymphocytes correlates with progressive loss of renal function and cardiovascular risk factors in chronic kidney disease. <i>European Journal of Pharmacology</i> , 2008, 593, 99-104.	1.7	20
38	Human and Mouse Homologs of the <i>Schizosaccharomyces pombe</i> rad17+Cell Cycle Checkpoint Control Gene. <i>Genomics</i> , 1999, 55, 219-228.	1.3	19
39	Phenotypic plasticity of <i>Escherichia coli</i> upon exposure to physical stress induced by ZnO nanorods. <i>Scientific Reports</i> , 2019, 9, 8575.	1.6	19
40	Increased SOCS expression in peripheral blood mononuclear cells of end stage renal disease patients is related to inflammation and dialysis modality. <i>European Journal of Pharmacology</i> , 2009, 602, 163-167.	1.7	13
41	Anti-oxidant sensitivity of donor age-related gene expression in cultured fibroblasts. <i>European Journal of Pharmacology</i> , 2006, 542, 154-161.	1.7	12
42	Advances in peptidic and peptidomimetic-based approaches to inhibit STAT signaling in human diseases. <i>Current Protein and Peptide Science</i> , 2016, 17, 135-146.	0.7	10
43	Molecular Properties and Medical Applications of Peptide Nucleic Acids. <i>Mini-Reviews in Medicinal Chemistry</i> , 2014, 14, 401-410.	1.1	10
44	Gene expression of energy and protein metabolism in hearts of hypertensive nitric oxide- or GSH-depleted mice. <i>European Journal of Pharmacology</i> , 2005, 513, 21-33.	1.7	8
45	Genetic characterization of Polish ccRCC patients: somatic mutation analysis of <i>PBRM1</i> , <i>BAP1</i> and <i>KDMC5</i> , genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA. <i>Oncotarget</i> , 2017, 8, 28558-28574.	0.8	8
46	Comparative screening and validation as a novel tool to identify STAT-specific inhibitors. <i>European Journal of Pharmacology</i> , 2014, 740, 417-420.	1.7	7
47	Genome-Wide Inhibition of Pro-atherogenic Gene Expression by Multi-STAT Targeting Compounds as a Novel Treatment Strategy of CVDs. <i>Frontiers in Immunology</i> , 2018, 9, 2141.	2.2	7
48	ESR Method in Monitoring of Nanoparticle Endocytosis in Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4388.	1.8	7
49	From Transcriptome to Behavior: Intranasal Injection of Late Passage Human Olfactory Stem Cells Displays Potential in a Rat Model of Parkinson's Disease. <i>ACS Chemical Neuroscience</i> , 2021, 12, 2209-2217.	1.7	7
50	CAVS: Novel in silico selection strategy of specific STAT inhibitory compounds. <i>Journal of Computational Science</i> , 2015, 10, 186-194.	1.5	5
51	STAT2-directed pathogen responses. <i>Oncotarget</i> , 2015, 6, 28525-28526.	0.8	5
52	Isolation, properties and chromosomal localization of four closely linked hamster interferon-alpha-encoding genes. <i>Gene</i> , 1995, 158, 295-300.	1.0	4
53	Editorial: STATs and IRFs in Innate Immunity: From Transcriptional Regulators to Therapeutic Targets. <i>Frontiers in Immunology</i> , 2019, 10, 1829.	2.2	1
54	SINBAD, structural, experimental and clinical characterization of STAT inhibitors and their potential applications. <i>Scientific Data</i> , 2022, 9, 139.	2.4	1

#	ARTICLE	IF	CITATIONS
55	Letter to the Editor. Cytokine and Growth Factor Reviews, 2016, 32, 1.	3.2	0